Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation

References

• Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med.357(25), 2601–2614 (2007).
   PubMed Web of Science ®Google Scholar
• Glenn J. Cytomegalovirus infections following renal transplantation. Rev. Infect. Dis.3(6), 1151–1178 (1981).
   PubMedGoogle Scholar
• Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant.6(2), 262–274 (2006).
   PubMed Web of Science ®Google Scholar
• Manuel O, Meylan PR, Rotman S, Fontana M, Moradpour D, Pascual M. Oral valganciclovir for cytomegalovirus colitis after liver transplantation. Transplantation83(2), 239–240 (2007).
   Google Scholar
• Lautenschlager I, Halme L, Hockerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl. Infect. Dis.8(1), 21–30 (2006).
   PubMed Web of Science ®Google Scholar
• Duncan SR, Paradis IL, Yousem SA et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am. Rev. Respir. Dis.146(6), 1419–1425 (1992).
   PubMedGoogle Scholar
• Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant.4(4), 611–620 (2004).
   PubMed Web of Science ®Google Scholar
• Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant.10(5), 1228–1237 (2010).
   PubMed Web of Science ®Google Scholar
• Freeman RB Jr. The ‘indirect’ effects of cytomegalovirus infection. Am. J. Transplant.9(11), 2453–2458 (2009).
   PubMed Web of Science ®Google Scholar
• Craigen JL, Yong KL, Jordan NJ et al. Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology92(1), 138–145 (1997).
   PubMed Web of Science ®Google Scholar
• Helantera I, Loginov R, Koskinen P, Tornroth T, Gronhagen-Riska C, Lautenschlager I. Persistent cytomegalovirus infection is associated with increased expression of TGF-β1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol. Dial. Transplant.20(4), 790–796 (2005).
   Google Scholar
• Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am. J. Transplant.8(7), 1486–1497 (2008).
   PubMedGoogle Scholar
• Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA261(24), 3561–3566 (1989).
   PubMed Web of Science ®Google Scholar
• Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus infection – an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation55(4), 851–857 (1993).
   PubMed Web of Science ®Google Scholar
• Bando K, Paradis IL, Similo S et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J. Thorac. Cardiovasc. Surg.110(1), 4–13 (1995).
   PubMed Web of Science ®Google Scholar
• Helantera I, Koskinen P, Finne P et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl. Int.19(11), 893–900 (2006).
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am. J. Transplant.4(6), 928–936 (2004).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin. Infect. Dis.23(3), 468–474 (1996).
   PubMed Web of Science ®Google Scholar
• George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am. J. Med.103(2), 106–113 (1997).
   PubMed Web of Science ®Google Scholar
• Humar A, Malkan G, Moussa G, Greig P, Levy G, Mazzulli T. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J. Infect. Dis.181(4), 1450–1453 (2000).
   PubMedGoogle Scholar
• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis.4(12), 725–738 (2004).
   PubMed Web of Science ®Google Scholar
• Leung Ki EL, Venetz JP, Meylan P, Lamoth F, Ruiz J, Pascual M. Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. Clin. Transplant.22(2), 245–249 (2008).
   PubMed Web of Science ®Google Scholar
• Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin. Infect. Dis.20(5), 1346–1353 (1995).
   PubMed Web of Science ®Google Scholar
• Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant.9(Suppl. 4), S78–S86 (2009).
   PubMed Web of Science ®Google Scholar
• Limaye AP, Bakthavatsalam R, Kim HW et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation78(9), 1390–1396 (2004).
   PubMedGoogle Scholar
• Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation81(12), 1645–1652 (2006).
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med.340(19), 1462–1470 (1999).
   PubMed Web of Science ®Google Scholar
• Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation83(3), 359–362 (2007).
   PubMedGoogle Scholar
• Cervera C, Lozano F, Saval N et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation83(11), 1493–1500 (2007).
   PubMedGoogle Scholar
• Razonable RR, Rivero A, Rodriguez A et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect. Dis.184(11), 1461–1464 (2001).
   PubMed Web of Science ®Google Scholar
• Brennan DC, Daller JA, Lake KD, Cibrik D, Del CD. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med.355(19), 1967–1977 (2006).
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J. Heart Lung Transplant.24(5), 517–525 (2005).
   PubMed Web of Science ®Google Scholar
• San JR, Aguado JM, Lumbreras C et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin. Infect. Dis.47(7), 875–882 (2008).
   Google Scholar
• Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, Degli-Esposti MA. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol. Cell Biol.85(1), 46–54 (2007).
   PubMed Web of Science ®Google Scholar
• Chou SW, Dennison KM. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J. Infect. Dis.163(6), 1229–1234 (1991).
   PubMed Web of Science ®Google Scholar
• Navarro D, Paz P, Tugizov S, Topp K, La VJ, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology197(1), 143–158 (1993).
   PubMedGoogle Scholar
• Manuel O, Asberg A, Pang X et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin. Infect. Dis.49(8), 1160–1166 (2009).
   PubMed Web of Science ®Google Scholar
• Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J. Virol.84(14), 7195–7203 (2010).
   PubMedGoogle Scholar
• Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation – challenging the status quo. Clin. Transplant.21(2), 149–158 (2007).
   PubMed Web of Science ®Google Scholar
• Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet350(9093), 1729–1733 (1997).
   PubMed Web of Science ®Google Scholar
• Manuel O, Venetz JP, Fellay J et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med. Wkly137(47–48), 669–676 (2007).
   PubMed Web of Science ®Google Scholar
• Meylan PR, Pascual M. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know. Clin. Infect. Dis.43(7), 881–883 (2006).
   Google Scholar
• Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet365(9477), 2105–2115 (2005).
   PubMed Web of Science ®Google Scholar
• Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med.143(12), 870–880 (2005).
   PubMed Web of Science ®Google Scholar
• Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr. Opin. Infect. Dis.20(4), 412–418 (2007).
   PubMedGoogle Scholar
• Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant.8(5), 975–983 (2008).
   PubMed Web of Science ®Google Scholar
• Danziger-Isakov L, Mark BG. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin. Transplant.23(3), 295–304 (2009).
   PubMed Web of Science ®Google Scholar
• Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am. J. Transplant.4(10), 1635–1642 (2004).
   PubMed Web of Science ®Google Scholar
• Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation91(8), 927–933 (2011).
   PubMedGoogle Scholar
• Diaz-Pedroche C, Lumbreras C, San JR et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation82(1), 30–35 (2006).
   PubMed Web of Science ®Google Scholar
• Muheim C, Vogel G, Seydoux C et al. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation74(2), 226–236 (2002).
   Google Scholar
• Singh N, Wannstedt C, Keyes L et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl.14(2), 240–244 (2008).
   Google Scholar
• Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant.8(1), 69–77 (2008).
   PubMed Web of Science ®Google Scholar
• Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin. Infect. Dis.43(7), 869–880 (2006).
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation89(7), 779–795 (2010).
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant.9(Suppl. 3), S1–S155 (2009).
   PubMed Web of Science ®Google Scholar
• Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci.89(6), 781–789 (2000).
   PubMed Web of Science ®Google Scholar
• Lai L, Xu Z, Zhou J, Lee KD, Amidon GL. Molecular basis of prodrug activation by human valacyclovirase, an α-amino acid ester hydrolase. J. Biol. Chem.283(14), 9318–9327 (2008).
   PubMed Web of Science ®Google Scholar
• Caldes A, Colom H, Armendariz Y et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob. Agents Chemother.53(11), 4816–4824 (2009).
   PubMed Web of Science ®Google Scholar
• Caldes A, Gil-Vernet S, Armendariz Y et al. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics. Transpl. Infect. Dis.12(3), 204–212 (2010).
   Google Scholar
• Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother.44(10), 2811–2815 (2000).
   PubMed Web of Science ®Google Scholar
• Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin. Pharmacokinet.48(6), 399–418 (2009).
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Jain A, Robson R, Mulgaonkar S, Freeman R, Bouw MR. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant. Proc.39(10), 3111–3116 (2007).
   PubMed Web of Science ®Google Scholar
• Welker H, Farhan M, Humar A, Washington C. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. Transplantation90(12), 1414–1419 (2010).
   PubMed Web of Science ®Google Scholar
• Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin. Pharmacokinet.44(5), 495–507 (2005).
   PubMed Web of Science ®Google Scholar
• Perrottet N, Csajka C, Pascual M et al. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob. Agents Chemother.53(7), 3017–3023 (2009).
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs65(6), 859–878 (2005).
   PubMed Web of Science ®Google Scholar
• Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis.10(Suppl. 3), S490–S494 (1988).
   PubMedGoogle Scholar
• Wiltshire H, Paya CV, Pescovitz MD et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation79(11), 1477–1483 (2005).
   PubMed Web of Science ®Google Scholar
• Perrottet N, Manuel O, Lamoth F et al. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. BMC Infect. Dis.10, 2 (2010).
   PubMed Web of Science ®Google Scholar
• Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One4(5), e5512 (2009).
   PubMed Web of Science ®Google Scholar
• Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant.8(1), 158–161 (2008).
   PubMed Web of Science ®Google Scholar
• Humar A, Limaye AP, Blumberg EA et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation90(12), 1427–1431 (2010).
   PubMed Web of Science ®Google Scholar
• Humar A, Peeters P, Abramowicz D et al. Response to questions regarding the design and results of the IMPACT trial. Am. J. Transplant.11(1), 177–178 (2011).
   Google Scholar
• Kalil AC, Sun J, Florescu DF. IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis. Am. J. Transplant.11(1), 18–21 (2011).
   Google Scholar
• Luan FL, Kommareddi M, Ojo AO. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Transplantation91(2), 237–244 (2011).
   PubMed Web of Science ®Google Scholar
• Blumberg EA, Hauser IA, Stanisic S et al. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation90(12), 1420–1426 (2010).
   PubMed Web of Science ®Google Scholar
• Asberg A, Humar A, Rollag H et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant.7(9), 2106–2113 (2007).
   PubMed Web of Science ®Google Scholar
• Lamoth F, Manuel O, Venetz JP, Faouzi M, Meylan P, Pascual M. What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation? Transplantation86(9), 1323–1324 (2008).
   PubMedGoogle Scholar
• Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis.46(6), 840–846 (2008).
   PubMed Web of Science ®Google Scholar
• Chamberlain CE, Penzak SR, Alfaro RM et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am. J. Transplant.8(6), 1297–1302 (2008).
   Web of Science ®Google Scholar
• Manuel O, Pascual M, Perrottet N et al. Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clin. Transplant.24(6), 794–800 (2010).
   PubMed Web of Science ®Google Scholar
• Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin. Infect. Dis.52(3), 313–321 (2011).
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. Is low-dose valganciclovir the same as appropriate-dose valganciclovir? Transplantation84(1), 126–127 (2007).
   Google Scholar
• Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis.189(9), 1615–1618 (2004).
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl. Infect. Dis.7(3–4), 166–170 (2005).
   PubMed Web of Science ®Google Scholar
• Hantz S, Garnier-Geoffroy F, Mazeron MC et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J. Antimicrob. Chemother.65(12), 2628–2640 (2010).
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Tan MB, Nicholls K, Walker RG, Cohney SJ. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients. Nephrology16(1), 113–117 (2011).
   PubMed Web of Science ®Google Scholar
• San JR, Yebra M, Lumbreras C et al. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. Clin. Transplant.23(5), 666–671 (2009).
   Google Scholar
• Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation91(2), 251–255 (2011).
   PubMedGoogle Scholar
• Danziger-Isakov L, Heeger PS. Clinical utility of measuring T-cell immunity to CMV in transplant recipients. Am. J. Transplant.9(5), 987–988 (2009).
   PubMedGoogle Scholar
• Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med.6, 29 (2008).
   PubMedGoogle Scholar
• Gratama JW, Boeckh M, Nakamura R et al. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood116(10), 1655–1662 (2010).
   PubMed Web of Science ®Google Scholar
• Mattes FM, Vargas A, Kopycinski J et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant.8(5), 990–999 (2008).
   PubMedGoogle Scholar
• Giulieri S, Manuel O. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev. Mol. Diagn.11(1), 17–25 (2011).
   PubMed Web of Science ®Google Scholar
• Walker S, Fazou C, Crough T et al.Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis.9(2), 165–170 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant.9(5), 1214–1222 (2009).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Limaye AP, Banks M et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann. Intern. Med.152(12), 761–769 (2010).
   PubMed Web of Science ®Google Scholar
• Perrottet N, Robatel C, Meylan P et al. Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. J. Antimicrob. Chemother.61(6), 1332–1335 (2008).
   PubMed Web of Science ®Google Scholar
• Kaul DR, Stoelben S, Cober E et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am. J. Transplant.11(5), 1079–1084 (2011).
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Stanton A, McCarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a Phase 2 randomised placebo-controlled trial. Lancet377(9773), 1256–1263 (2011).
   PubMed Web of Science ®Google Scholar